This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Inovio Pharmaceuticals Class Action Deadline
Business class action

Inovio Pharmaceuticals Class Action Deadline

Analysis based on 11 articles · First reported Apr 01, 2026 · Last updated Apr 06, 2026

Sentiment
-50
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Rhythm Pharmaceuticals, Inc. could lead to significant financial liabilities for the company, potentially impacting its stock price negatively. Investors who purchased Rhythm Pharmaceuticals securities during the Class Period may be entitled to compensation, which could affect their investment portfolios.

Biotechnology Legal Services
Event Summary

Rosen Law Firm is reminding investors of Rhythm Pharmaceuticals, Inc. about the April 7, 2026 lead plaintiff deadline for a class action lawsuit. The lawsuit alleges that Rhythm Pharmaceuticals made false and misleading statements between October 10, 2023, and December 26, 2025. These statements concerned deficiencies in the manufacturing of Rhythm Pharmaceuticals's CELLECTRA device, the unlikelihood of submitting the INO-3107 Biologics License Application to the United States — Food and Drug Administration by the second half of 2024, and insufficient information to justify accelerated approval or priority review for INO-3107. As a result, the regulatory and commercial prospects of INO-3107 were allegedly overstated, causing investors to suffer damages when the true details emerged.

Entities Involved
stock
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its CELLECTRA device and INO-3107 Biologics License Application.
Importance 100.0 Sentiment -70.0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Rhythm Pharmaceuticals, Inc. securities are traded.
Importance 10.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
Nasdaq-100 related ↔ Rosen Law Firm
Nasdaq-100 related ↔ Philip Kim
Nasdaq-100 related ↔ Lawrence Rosen
Nasdaq-100 related ↔ United States — Food and Drug Administration
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ United States — Food and Drug Administration
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
Philip Kim related ↔ United States — Food and Drug Administration
Lawrence Rosen related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.